121 related articles for article (PubMed ID: 16498608)
1. Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
Bové J; Serrats J; Mengod G; Cortés R; Aguilar E; Marin C
Synapse; 2006 Jun; 59(7):435-44. PubMed ID: 16498608
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of 8-(3-chlorostryryl) caffeine on levodopa-induced motor fluctuation is associated with intracellular signaling pathway in 6-OHDA-lesioned rats.
Song L; Kong M; Ma Y; Ba M; Liu Z
Brain Res; 2009 Jun; 1276():171-9. PubMed ID: 19393228
[TBL] [Abstract][Full Text] [Related]
3. Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats.
Bové J; Marin C; Bonastre M; Tolosa E
Synapse; 2002 Dec; 46(4):251-7. PubMed ID: 12373740
[TBL] [Abstract][Full Text] [Related]
4. Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats.
Marin C; Aguilar E; Mengod G; Cortés R; Obeso JA
Eur J Neurosci; 2009 Sep; 30(5):823-32. PubMed ID: 19712101
[TBL] [Abstract][Full Text] [Related]
5. The kappa opioid agonist U50,488 potentiates 6-hydroxydopamine-induced neurotoxicity on dopaminergic neurons.
Marin C; Bové J; Serrats J; Cortés R; Mengod G; Tolosa E
Exp Neurol; 2005 Jan; 191(1):41-52. PubMed ID: 15589511
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.
Bové J; Serrats J; Mengod G; Cortés R; Tolosa E; Marin C
Exp Brain Res; 2005 Sep; 165(3):362-74. PubMed ID: 15968457
[TBL] [Abstract][Full Text] [Related]
7. Effect of acute and chronic administration of U50,488, a kappa opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa.
Marin C; Bové J; Bonastre M; Tolosa E
Exp Neurol; 2003 Sep; 183(1):66-73. PubMed ID: 12957489
[TBL] [Abstract][Full Text] [Related]
8. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Pavón N; Martín AB; Mendialdua A; Moratalla R
Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
[TBL] [Abstract][Full Text] [Related]
9. CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
Huang YX; Luo WF; Li D; Hu WD; Liu CF
Brain Res; 2011 Feb; 1376():113-21. PubMed ID: 21195062
[TBL] [Abstract][Full Text] [Related]
10. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
[TBL] [Abstract][Full Text] [Related]
11. Concomitant short- and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study.
Marin C; Aguilar E; Mengod G; Cortés R; Obeso JA
Eur J Neurosci; 2007 Jan; 25(1):259-69. PubMed ID: 17241287
[TBL] [Abstract][Full Text] [Related]
12. LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats.
Marin C; Jiménez A; Bonastre M; Vila M; Agid Y; Hirsch EC; Tolosa E
Synapse; 2001 Oct; 42(1):40-7. PubMed ID: 11668589
[TBL] [Abstract][Full Text] [Related]
13. Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398.
Lane EL; Cheetham S; Jenner P
J Neural Transm (Vienna); 2008; 115(3):423-9. PubMed ID: 18250952
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression.
Duty S; Brotchie JM
Exp Neurol; 1997 Apr; 144(2):423-32. PubMed ID: 9168843
[TBL] [Abstract][Full Text] [Related]
15. Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.
Marin C; Aguilar E; Mengod G; Cortés R; Rodríguez-Oroz MC; Obeso JA
Neurobiol Dis; 2008 Dec; 32(3):340-8. PubMed ID: 18722529
[TBL] [Abstract][Full Text] [Related]
16. Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.
Lee J; Gomez-Ramirez J; Johnston TH; Visanji N; Brotchie JM
Synapse; 2008 Apr; 62(4):310-3. PubMed ID: 18241048
[TBL] [Abstract][Full Text] [Related]
17. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Mov Disord; 2006 Jan; 21(1):9-17. PubMed ID: 16127720
[TBL] [Abstract][Full Text] [Related]
18. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
[TBL] [Abstract][Full Text] [Related]
19. CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats.
Aguiar LM; Macêdo DS; Vasconcelos SM; Oliveira AA; de Sousa FC; Viana GS
Brain Res; 2008 Jan; 1191():192-9. PubMed ID: 18164694
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.
Carta AR; Pinna A; Cauli O; Morelli M
Synapse; 2002 Jun; 44(3):166-74. PubMed ID: 11954048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
